After months of dose adjustments, changing eating habits and watching the scale move, reaching your goal weight can feel like the obvious finish line.

Then comes a surprisingly complicated question:

Now what?

For people using GLP-1-based weight-management medications, reaching a target weight does not automatically mean the prescription ends. Current obesity-treatment guidance increasingly treats maintenance as another phase of care, because obesity is a chronic condition and weight can recur when an effective treatment is removed.

That does not mean everybody must take exactly the same medication at exactly the same dose forever. It means the decision deserves more planning than “I hit my number, so I stop.”

Key takeaways

• Reaching goal weight may change the purpose of treatment rather than end it. The objective can shift from additional weight reduction to maintaining weight and associated health improvements.
• Weight regain after stopping is common in clinical studies. Semaglutide and tirzepatide withdrawal trials found substantially more regain after medication was withdrawn than when treatment continued.
• Regaining every pound is not inevitable. Results are averages, and newer meta-analyses show considerable variation between studies and individuals.
• There is no universal “GLP-1 maintenance dose.” Approved maintenance doses differ by drug, and contemporary guidance supports individualizing treatment according to response, health benefits and tolerability.
• Stopping is still an option for some patients. Cost, adverse effects, preferences, pregnancy considerations and other health factors may change the risk-benefit calculation. The important point is to make that decision with the prescribing clinician and have a follow-up plan.

Why goal weight does not automatically mean it is time to stop

Prescription obesity medications are different from a short course of antibiotics. FDA labeling for current weight-management products explicitly includes long-term weight reduction or maintenance among their uses.

For adults using Wegovy injection for weight reduction, the current U.S. prescribing information lists 1.7 mg or 2.4 mg weekly as maintenance doses, with 2.4 mg recommended in most adults. Zepbound labeling lists 5 mg, 10 mg or 15 mg weekly as maintenance doses for weight reduction and long-term maintenance.

That wording matters. The maintenance phase is not evidence that the initial treatment “failed.” Maintaining a lower body weight can itself be the treatment outcome.

The 2026 Standards of Care in Overweight and Obesity recommend continuing obesity medication after treatment goals have been achieved when appropriate, because discontinuation commonly leads to renewed weight gain and loss of some associated health improvements.

What happens if you stop a GLP-1 after reaching goal weight?

This is where some of the clearest evidence comes from randomized withdrawal studies.

What happened after semaglutide was stopped?

In the STEP 1 extension, participants receiving semaglutide 2.4 mg had lost an average of 17.3% of their starting body weight after 68 weeks. One year after semaglutide and the trial lifestyle intervention were withdrawn, participants had regained an average of 11.6 percentage points—roughly two-thirds of the weight they had previously lost. Several cardiometabolic improvements also moved back toward baseline.

Another semaglutide trial, STEP 4, produced a similar contrast. After an initial semaglutide treatment period, participants randomized to continue semaglutide lost another 7.9% on average over the following 48 weeks, while those switched to placebo gained 6.9%.

What happened after tirzepatide was stopped?

SURMOUNT-4 followed adults who first completed 36 weeks of tirzepatide and had lost an average of 20.9% of their body weight.

During the following 52 weeks, participants who continued tirzepatide lost another 5.5% on average. Those switched to placebo gained 14.0%. Nearly 90% of the continued-treatment group retained at least 80% of their initial weight reduction, compared with 16.6% of those switched to placebo.

These trials strongly support continued pharmacotherapy for maintaining treatment effects. But they do not prove that every person stopping a GLP-1 will regain the same amount.

A 2026 systematic review of GLP-1 receptor agonist discontinuation estimated that approximately 60% of weight lost during treatment had been regained at one year across the randomized trials it analyzed. The authors found a consistent rebound pattern but also substantial uncertainty around longer-term trajectories.

Another major 2026 BMJ review concluded that weight-management medication withdrawal was followed by relatively rapid average regain and deterioration in cardiometabolic markers.

The useful message is therefore “regain is a meaningful risk,” not “regain is guaranteed.”

What can GLP-1 maintenance actually look like?

There is more than one possible maintenance strategy.

Approach	What it means	Evidence/considerations
Continue an approved maintenance dose	Keep taking the medication at a labeled maintenance dose	Strongest evidence from continuation and withdrawal trials
Individualize the dose	Clinician adjusts treatment to balance weight stability, health benefits and side effects	Supported in 2026 obesity-treatment guidance
Consider reduced or intermittent treatment	Lower or less frequent treatment under medical supervision	Discussed in current guidance, but evidence is less established than standard continued dosing
Stop with close monitoring	Discontinue and monitor weight, appetite and health markers	Reasonable in selected circumstances, but recurrence should be anticipated and monitored

Current standards specifically state that the individualized maintenance dose does not necessarily need to be the maximum approved dose. They also discuss lowest-effective-dose and intermittent strategies as possibilities under shared decision-making. However, some lower-dose or altered-frequency regimens may fall outside FDA-approved dosing, and the evidence base is less mature.

This is an area where online advice can become misleading. “Microdosing,” stretching injections or changing the schedule independently is not the same thing as a clinician-directed maintenance strategy.

So what is the right GLP-1 maintenance dose?

There is no single number.

For current FDA-approved injectable weight-management treatment:

• Wegovy: 1.7 mg or 2.4 mg weekly are labeled adult maintenance doses for weight reduction, with 2.4 mg recommended.
• Zepbound: 5 mg, 10 mg or 15 mg weekly are labeled maintenance doses for weight reduction and long-term maintenance. Treatment response and tolerability should guide selection.

Those are prescribing-label doses, not instructions for an individual reader. A clinician may have reasons to select, change or discontinue treatment based on the medication being used, adverse effects, weight trajectory, other health conditions and treatment goals.

Maintenance should track more than one number on the scale

A good follow-up program should not simply wait for enough weight to return before acting.

Maintenance appointments can assess:

• whether body weight is relatively stable over time;
• whether hunger, cravings or eating patterns are changing;
• medication tolerance and side effects;
• adherence and injection technique where relevant;
• blood pressure, glucose, lipids or other clinically relevant markers;
• nutrition and physical activity;
• whether further weight loss would actually be appropriate;
• whether the cost and burden of treatment remain acceptable.

The last point matters. A medication can be clinically effective and still become impractical because of insurance changes, cash-pay costs or side effects. Those tradeoffs belong in shared decision-making rather than being treated as a lack of commitment.

What if you want to stop?

Stopping a GLP-1 does not need to be framed as failure.

Some people will eventually prefer to discontinue treatment, while others may need to stop because of adverse effects, contraindications, changing health circumstances, access or cost.

Current guidance allows for stopping obesity medication followed by close weight monitoring as one possible individualized strategy. But evidence that lifestyle measures can fully substitute for the medication after withdrawal remains limited. The ADA specifically notes that commonly recommended maintenance behaviors have not been validated as a reliable method for preventing post-GLP-1 weight recurrence.

That does not make nutrition, physical activity, sleep or behavioral support unimportant. It means they should not be sold as a guaranteed antidote to biological weight regain.

Before stopping, a more useful conversation is:

• What amount of weight change would trigger reassessment?
• How frequently should I follow up?
• Which health markers should continue to be monitored?
• What should I do if hunger increases substantially?
• Would restarting treatment be an option?
• Is there another maintenance strategy that reduces cost or side effects?

What your telehealth clinic should be able to explain

A credible GLP-1 program should have an answer for maintenance before you reach your goal weight.

Ask:

• What happens when I reach the target we agreed on?
• Do you routinely offer long-term maintenance care?
• Who decides whether my dose changes?
• Is the proposed maintenance dose FDA-labeled for this medication?
• If not, why is an off-label strategy being recommended?
• How often will my weight and health markers be reviewed?
• Does the program price change during maintenance?
• Can I contact a clinician if appetite or weight begins to rebound?
• What happens if I decide I want to stop?
• What follow-up is available after discontinuation?

Be cautious of any program promising that one specific maintenance schedule works for everyone, telling patients to alter dosing without clinical review, or implying that substantial weight regain is either completely inevitable or completely preventable.

The real maintenance conversation

The difficult part about reaching goal weight is discovering that there may not be a clean ending.

For many people, that is simply the reality of treating a chronic condition. The medication may have helped create a lower-weight state that still requires treatment to maintain.

For others, reducing, changing or eventually stopping medication may be reasonable.

The goal of GLP-1 maintenance is therefore not necessarily to keep taking as much medication as possible—or to prove you can maintain your weight without it. It is to find the least burdensome long-term strategy that preserves meaningful health benefits and remains acceptable to you, with a qualified clinician helping determine when that strategy should change.

Frequently asked questions

Do you have to stay on a GLP-1 forever after losing weight?

Not necessarily, but current obesity-treatment guidance generally supports continuing effective pharmacotherapy after weight-loss goals have been reached because stopping frequently leads to weight recurrence. The decision should account for treatment benefit, side effects, cost, other health conditions and patient preference.

What is a GLP-1 maintenance dose?

It is the dose used for ongoing treatment after dose escalation, but there is no universal GLP-1 maintenance dose. Current Wegovy and Zepbound labeling provides different approved maintenance-dose options. Clinicians can also individualize long-term therapy, although a dose or schedule outside the approved label may constitute off-label use.

Will I regain weight if I stop taking a GLP-1?

Weight regain is common, but the amount varies. In the STEP 1 extension, participants regained roughly two-thirds of their previous semaglutide-associated weight loss on average within one year of withdrawal. In SURMOUNT-4, people switched from tirzepatide to placebo regained substantial weight over 52 weeks. Neither result predicts precisely what will happen to an individual patient.

Can my GLP-1 dose be lowered once I reach goal weight?

Potentially. Current 2026 obesity pharmacotherapy standards recommend individualizing maintenance doses and state that maintenance need not always use the maximum approved dose. Exactly which dose is appropriate depends on the medication and clinical circumstances.

Can I take my GLP-1 less often for maintenance?

Reduced-frequency or intermittent treatment is being explored, and current guidelines mention intermittent therapy as a possible individualized strategy. However, evidence is considerably less established than for conventional continued treatment, and changing injection timing without prescriber guidance is not recommended.

What happens if my appetite returns after stopping?

The experience varies. A return of hunger or food preoccupation may make weight maintenance harder for some people, but appetite alone should not dictate treatment changes. Contact the prescribing clinician if appetite changes are accompanied by a sustained weight trend or if you are struggling with the maintenance plan.

How much weight regain is considered a problem?

There is no single number that applies to every person. A clinician may consider the overall trend, percentage of prior loss regained, cardiometabolic health, appetite, quality of life and original treatment goals. Agreeing on a threshold for reassessment before stopping medication can make maintenance considerably less reactive.